title: Treatment of unprotected left main disease with drug-eluting stents in patients at high risk for coronary artery bypass grafting.
abstract: BACKGROUND
  Percutaneous coronary intervention (PCI) for high-grade stenosis of the left main coronary artery with bare-metal stents has been limited by restenosis, and most patients are managed with coronary artery bypass grafting (CABG). Recently, drug-eluting stents (DES) have reduced instent restenosis after PCI, but their role in the treatment of left main disease remains unclear.
  
  
  OBJECTIVE
  The aim of this study was to determine the outcomes after utilizing DES to treat left main disease.
  
  
  METHODS
  Twenty consecutive symptomatic patients with >50% angiographic stenosis of the left main coronary artery with no prior history of CABG ["unprotected left main" (ULM)] underwent PCI with DES. Patients were divided into two groups based on the presence (Group A, n=5) or absence (Group B, n=15) of preprocedural cardiogenic shock. At follow up (median, 14 months), cumulative major adverse cardiac events (MACE-death, myocardial infarction, or target vessel revascularization) were determined.
  
  
  RESULTS
  Sixteen (80%) of 20 patients were at high risk for CABG because of comorbidity, advanced age, or cardiogenic shock. Procedural success was 100% (20/20). Three of five patients in Group A (60%) died in hospital and the two surviving patients experienced no MACE at follow up. In Group B (n=15), there was no in-hospital MACE, but one patient died suddenly 8 weeks postprocedure [cumulative MACE of 7% (1/15)].
  
  
  CONCLUSIONS
  Our study demonstrates the feasibility of ULM treatment with DES with acceptable medium-term outcomes. While CABG remains the best form of revascularization for the majority of patients with ULM, DES should be considered in those who are at high risk.
authors.affiliation: Department of Cardiology, Austin Hospital, Melbourne, Victoria 3084, Australia.
authors.forename: Peter
authors.initials: P
authors.lastname: Barlis
authors.forename: Mark
authors.initials: M
authors.lastname: Horrigan
authors.forename: Safari
authors.initials: S
authors.lastname: Elis
authors.forename: Robert
authors.initials: R
authors.lastname: Chan
authors.forename: Michael
authors.initials: M
authors.lastname: Wong
authors.forename: Omar
authors.initials: O
authors.lastname: Farouque
authors.forename: George
authors.initials: G
authors.lastname: Proimos
authors.forename: Andrew E
authors.initials: AE
authors.lastname: Ajani
authors.forename: David J
authors.initials: DJ
authors.lastname: Clark
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality; D017023:Coronary Angiography; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011446:Prospective Studies; D011474:Prosthesis Design; D012107:Research Design; D018570:Risk Assessment; D012720:Severity of Illness Index; D012770:Shock, Cardiogenic / Q000209:etiology / Q000401:mortality; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents